Assessment of ERα and PGR status by immunohistochemistry guides treatment decisions for breast cancer, as PGR is an ERα‐regulated gene and used as a biomarker of ERα activation (Lee and Gorski, 1996). This evidence concerns the gene ESR1 and breast cancer.